Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy
- 19 April 2010
- journal article
- research article
- Published by Elsevier BV in Vaccine
- Vol. 28 (18), 3086-3094
- https://doi.org/10.1016/j.vaccine.2010.02.065
Abstract
No abstract availableKeywords
Funding Information
- U.S. NIAID (R01 AI 52337)
- Australian National Health and Medical Research Council
This publication has 43 references indexed in Scilit:
- Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancyVaccine, 2010
- Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimatesThe Lancet, 2009
- Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccineVaccine, 2009
- Reconsideration of the Use of Meningococcal Polysaccharide VaccineThe Pediatric Infectious Disease Journal, 2007
- Discovery of a New Capsular Serotype (6C) within Serogroup 6 ofStreptococcus pneumoniaeJournal of Clinical Microbiology, 2007
- Functional Antibodies Elicited by Two Heptavalent Pneumococcal Conjugate Vaccines in the Finnish Otitis Media Vaccine TrialInfection and Immunity, 2007
- Pneumococcal Type 22F Polysaccharide Absorption Improves the Specificity of a Pneumococcal-Polysaccharide Enzyme-Linked Immunosorbent AssayClinical and Diagnostic Laboratory Immunology, 2001
- Conclusions from the WHO multicenter study of serious infections in young infantsThe Pediatric Infectious Disease Journal, 1999
- Dose dependency of antibody response in infants and children to pneumococcal polysaccharides conjugated to tetanus toxoidVaccine, 1999
- Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhoodVaccine, 1999